Plans to Remove Potentially Carcinogenic Contaminants from Januvia, Janumet Outlined By Merck
Merck indicates it will remove nitrosamine contaminants from Januvia and Janumet by the end of 2023.
Topic Archives: Valsartan
-
-
Valsartan NDMA Lawsuits Cleared To Move Forward, After Motion for Reconsideration Rejected
A federal judge has cleared Valsartan NDMA lawsuits to proceed after rejecting a call by defendants to reconsider the admissibility of plaintiffs' expert witnesses following the recent dismissal of Zantac…
-
FDA Inspectors Say Valisure’s Former Pharmacy Division Failed to Meet Drug Security Requirements
An FDA inspection of the independent testing lab Valisure's former pharmacy division found it failed to identify illegitimate drug products and raised questions about the company's knowledge of the Food,…
-
Valsartan Recall Lawsuits
Side effects of recalled valsartan may increase the risk of cancer, due to an impurity discovered in certain generic versions of the hypertension drug.
-
Potentially Cancer-Causing Contaminant Found In Januvia: FDA
Some batches of Januvia, a diabetes drug, contain high levels of nitrosamines which could increase cancer risks, the FDA warns.
-
Accupril Recall Issued Over Nitrosamine Contamination
Pfizer is recalling five lots of Accupril, a hypertension drug, due to the risk of nitrosamine contamination and long-term cancer risk.
-
Pfizer Announces Accuretic Recall in U.S. Over Nitrosamine Contamination
Pfizer is recalling several lots of Accuretic hypertension drugs due to the presence of potentially cancer-causing chemicals.
-
Valsartan Settlement Masters Appointed To Advance Negotiations in MDL
Two former district judges have been appointed as valsartan settlement special masters to help bring about a resolution to the litigation.
-
Accuretic Recall Announced In Canada Over Nitrosamine Contamination In Another Pfizer Hypertension Drug
Canadian health regulators have announced an Accuretic recall, indicating the Pfizer hypertension drug contains levels of cancer-causing chemicals above the acceptable amounts.
-
Extended Use of Valsartan and Other Angiotensin-Receptor Blockers May Increase Cancer Risk: Study
Valsartan and similar hypertension drugs may carry an increased risk of cancer with long-term use, according to the findings of a new study.
